Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Replimune Group, Inc. REPL
$19.10
+$0.36 (1.89%)
На 18:01, 12 мая 2023
+156.54%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1046417850.00000000
-
week52high
29.52
-
week52low
13.14
-
Revenue
0
-
P/E TTM
-7
-
Beta
1.65158500
-
EPS
-2.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
17 мая 2023 г. в 12:00
Описание компании
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 17 авг 2022 г. |
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| Wedbush | Outperform | Outperform | 24 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 мая 2022 г. |
| JP Morgan | Overweight | Overweight | 04 апр 2022 г. |
| SVB Leerink | Outperform | Outperform | 03 окт 2022 г. |
| BMO Capital | Outperform | Outperform | 14 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 16 авг 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. | |
| BMO Capital | Outperform | Outperform | 12 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 07 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Esposito Pamela | D | 36203 | 15000 | 09 дек 2022 г. |
| Esposito Pamela | D | 229402 | 15000 | 09 дек 2022 г. |
| Esposito Pamela | A | 244402 | 15000 | 09 дек 2022 г. |
| Xynos Konstantinos | A | 26250 | 26250 | 01 дек 2022 г. |
| Xynos Konstantinos | A | 70798 | 17500 | 01 дек 2022 г. |
| Love Colin | D | 765735 | 6324 | 16 мая 2022 г. |
| Esposito Pamela | D | 229402 | 3507 | 16 мая 2022 г. |
| Lewis Tanya | D | 120360 | 5473 | 16 мая 2022 г. |
| Franchi Jean M. | D | 95099 | 3436 | 16 мая 2022 г. |
| Astley-Sparke Philip | D | 1401080 | 9632 | 16 мая 2022 г. |
Новостная лента
Replimune to Present at Two Upcoming Investor Conferences
GlobeNewsWire
08 мар 2023 г. в 08:00
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
Replimune Group, Inc. (REPL) Loses -14.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
24 февр 2023 г. в 11:18
Replimune Group, Inc. (REPL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Replimune Group, Inc. (REPL) is on the Move, Here's Why the Trend Could be Sustainable
Zacks Investment Research
09 февр 2023 г. в 10:34
Replimune Group, Inc. (REPL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Recent Price Trend in Replimune Group, Inc. (REPL) is Your Friend, Here's Why
Zacks Investment Research
06 янв 2023 г. в 10:32
Replimune Group, Inc. (REPL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 08:00
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 AM PT at the Westin St. Francis Hotel in San Francisco, CA.